Literature DB >> 24419136

Reply to E.J. Moylan et al.

Sandra M Swain1, Gong Tang, Charles E Geyer.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24419136      PMCID: PMC3918541          DOI: 10.1200/JCO.2013.53.8744

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer?

Authors:  Eugene J Moylan; Louise C Connell; Seamus O'Reilly
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

6.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Authors:  Sandra M Swain; Gong Tang; Charles E Geyer; Priya Rastogi; James N Atkins; Paul P Donnellan; Louis Fehrenbacher; Catherine A Azar; André Robidoux; Jonathan A Polikoff; Adam M Brufsky; David D Biggs; Edward A Levine; John L Zapas; Louise Provencher; Donald W Northfelt; Soonmyung Paik; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

Review 7.  Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Luisa Bonilla; Irit Ben-Aharon; Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Salomon M Stemmer
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.